Skip to navigationSkip to contentSkip to footerHelp using this website - Accessibility statement
  • Zelira Therapeutics Limited

    Research, development and commercialization of clinically validated cannabinoid-based medicines.

    ZLD$0.470
    0.00

    Data last updated:May 31, 2024 – 2.44pm. Data is 20 mins delayed.

    Previous Close

    0.470

    Open

    0.470

    Day Range

    0.470 - 0.470

    52 Week Range

    0.450 - 3.350

    Volume

    649

    Value

    305

    Bid

    0.470

    Ask

    0.490

    Dividend Yield

    0.00%

    P/E Ratio

    0.00

    Market Cap

    5.333M

    Total Issue

    11,347,155

    ASX Announcements

    Market Sensitive

    HOPE SPV receives US$681,000 third tranche of funding

    Periodic Reports - Other, Progress Report

    • May 23, 2024
    • 2 pages

    Market Sensitive

    Appendix 4C Cash Flow Report

    CTE – Third Quarter Cashflow Report

    • Apr 29, 2024
    • 5 pages

    Market Sensitive

    March 2024 Quarterly Activities Report

    CTE - Third Quarter Activity Report

    • Apr 29, 2024
    • 5 pages

    Market Sensitive

    Zelira receives $919,000 R&D Tax Incentive Scheme Refund

    Progress Report, Company Administration - Other

    • Apr 15, 2024
    • 2 pages

    Market Sensitive

    Appendix 4D & FY24 Interim Financial Report

    Half Yearly Report, Half Year Audit Review, Half Year Directors' Statement, Half Year Accounts, Half Year Directors' Report

    • Feb 22, 2024
    • 28 pages

    View all ZLD announcements

    TODAY

    No stories for Zelira Therapeutics Limited are available.

    Search afr.com for Zelira Therapeutics Limited stories

    Copyright © 2024. Company information displayed on The Australian Financial Review is sourced from Morningstar and ASX and is subject to their terms and conditions as set out in our Terms of Use. The Australian Financial Review does not accept any responsibility for the accuracy and/or completeness of such data or information.